Frontlight ResearchEarly access
Taking people in United StatesPhase 2
KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury
Key facts
- Who runs it
- Irma Fleming
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 12 people, planned
- Started
- 24 Aug 2026
- Expected to end
- 1 Apr 2028
- Type of study
- Interventional
- Treatments tested
- Preparatory Session
- Ketamine-assisted Psychotherapy Session #1
- Ketamine-assisted Psychotherapy Session #2
- Integration Session
- Record updated
- 27 August 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Subjects 18 - 65 yrs with > 15 % Total Body Surface Area Burns
- National Stressful Events Survey Acute Stress Disorder Short Scale (NSESSS) average total score>= 2 (severity scale of none (0), mild (1), moderate (2), severe (3), or extreme (4) ) prior to discharge from UUH
Who cannot take part
- Allergy or previous adverse reactions to ketamine
- Pending surgical interventions
- Physical limitations from burn injury that preclude safe travel to outpatient visits or positioning for therapy
- Current or prior history of PTSD diagnosis
- Receiving ketamine treatments for psychiatric condition within the past 6 months
- Subjects taking prohibited medications. A washout period of prohibited medications for a period of at least five half-lives should occur prior to study registration. These medications include antipsychotic medications, doses of benzodiazepines in excess of 20mg diazepam equivalents per day
- Active systemic infection, sepsis, or hemodynamic instability
- Personal history or first- or second-degree relatives with schizophrenia, bipolar affective disorder, delusional disorder, schizoaffective disorder, psychosis, or other psychotic spectrum illness
- Currently meeting DSM-5 criteria for Dissociative Disorder, or other psychiatric conditions judged to be incompatible with the establishment of rapport or safe exposure to ketamine
- Currently meeting DSM-5 criteria for Cluster B Personality Disorder
- Current or history within the last two years of meeting DSM-V criteria of substance use disorder (excluding caffeine and nicotine)
- Current substance use disorders may be identified through the drug urine screening test or undergoing treatment (methadone/Suboxone)
- Congestive heart failure, including all New York Heart Association Classes
- Angina pectoris, cardiac hypertrophy, cardiac ischemia, myocardial infarction
- Uncontrolled hypertension at the time of enrollment (BP>140 systolic or 90 diastolic), coronary artery disease, artificial heart valve
- History of hypersensitivity to ketamine
- Seizure disorder
- Moderate to severe dementia
- History of significant traumatic brain injury
- Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, [patients may not receive the drug through a feeding tube], social/ psychological issues, etc.)
- Prolonged or congenital long QT syndrome (>450 ms), serious cardiac arrhythmias, tachycardia, a clinically significant screening ECG abnormality
- Lack of reliable transportation, caregiver support, or housing stability
- Language barrier
- Severe depression requiring immediate standard-of-care treatment (e.g., hospitalization)
- Suicidal ideation over the past month as assessed as a yes to question 3, 4, or 5 on the Columbia-Suicide Severity Rating Scale, Suicidal Ideation section
- Requires the use of supplemental oxygen
- Require Propranolol for Burn Hypermetabolism
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial is currently available in United States.
- University Of Utah HealthSalt Lake City, United StatesContact: Claire Ausbeck, BATaking people
About the trial
What the trial wants to find out
A study looking at the safety and tolerability of KAP (Ketamine-Assisted Psychotherapy) in the burn population.
The group in the trial
- Ketamine-Assisted PsychotherapyTreatment being tested
All 12 study participants will be assigned to receive KAP treatment.
Treatment: Preparatory Session, Ketamine-assisted Psychotherapy Session #1, Ketamine-assisted Psychotherapy Session #2, and Integration Session
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07563296, who can take part
- Record updated
- 27 August 2026